Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver ...

Xero CEO upbeat on US payment push despite margin squeeze from Melio deal

Xero CEO Sukhinder Singh Cassidy told CNBC’s Squawk Box Asia she remains bullish on the company’s US payments strategy ...